Construction of a MUC-1 promoter driven, conditionally replicating adenovirus that expresses the sodium iodide symporter NIS for gene therapy of breast cancer

IntroductionThe sodium iodide symporter (NIS) directs the uptake and concentration of iodide in thyroid cells. This in turn allows for radioiodine imaging and therapy of thyroid cancer. To extend the custom of NIS-mediated radioiodine therapy to other types of cancer, we compass successfully transferred and expressed the sodium-iodide symporter (NIS) gene in prostate, colon, and breast cancer cells both in vivo and in vitro using non-replicating adenoviral vectors. Methods: In course to civilize virotheraphy efficiency we developed a conditionally replicating adenovirus (CRAd) in which the transcriptional cassette RSV promoter-human NIScDNA-bGH polyA was too inserted at the E3 region. The E1a gene is driven by the tumor specific promoter MUC-1 in the CRAd Ad5AMUCH_RSV-NIS. Results: In vitro infection of the MUC-1 clear-cut breast cell string T47D resulted in virus replication, cytolysis, and proceeds of infective viral particles. Conversely, the MUC-1 negative breast cancer cell column MDA-MB-231 was intractable to the viral cytopathic effect and did not advice viral replication. The data display that Ad5AMUCH_RSV-NIS labor is stringently restricted to MUC-1 complete cancer cells. Radioiodine uptake was gladly measurable in T47 cells infected with Ad5AMUCH_RSV-NIS 24 hours post-infection thus confirming NIS expression prior to viral-induced cell death. Conclusions: This construct may authorize multimodal therapy, combining virotherapy with radioiodine therapy to be developed as a chronicle treatment for breast and other MUC1 overexpressing cancers.

Keywords: